Development of novel agents and combinations for renal carcinoma

Update on Cancer Therapeutics

Volumn 3, Issue 2, 2008, Pages 97-103

  Galsky, Matthew D ^a   Sonpavde, Guru ^a   Kapil, Ranjit ^b   Fleming, Mark T ^a   Kondagunta, G Varuni ^a   Hutson, Thomas E ^a   Sternberg, Cora ^c  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b Touro College and University System   (United States)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Metastatic; Renal carcinoma; Targeted therapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; LAPATINIB; MEGESTROL ACETATE; PAZOPANIB; PERIFOSINE; PLACEBO; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TRIACYLGLYCEROL LIPASE;

ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TOLERABILITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY CARCINOMA; KIDNEY METASTASIS; MACULOPAPULAR RASH; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT MONITORING; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SIDE EFFECT; THERAPY EFFECT; THROMBOCYTOPENIA; THYROID FUNCTION TEST; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

EID: 57449110915     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2008.11.001     Document Type: Review

References (33)

1. Kim W.Y., and Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 22 (2004) 4991-5004
2. Hanna S.C., Heathcote S.A., and Kim W.Y. mTOR pathway in renal cell carcinoma. Expert Rev Anticancer Ther 8 (2008) 283-292
3. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
4. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
5. Rini B.I., Halabi S., Rosenberg J.E., et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. ASCO Genitourinary Oncol. Symp. (2008) [Abstract #350]
6. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
7. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
8. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
9. Figlin R., Hutson T.E., Tomczak P., et al. Overall survival with sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 26 (2008) [Abstract #5024]
10. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
11. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
12. Szczylik C., Demkow T., Staehler M., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. Proc Am Soc Clin Oncol 25 (2007) [Abstract 5025]
13. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
14. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
15. Motzer R.J., Escudier B., Oudard S., et al. RAD001 plus best supportive care vs BSC plus placebo in patients with metastatic renal cell carcinoma, after progression on VEGF-r TKI therapy. Proc Am Soc Clin Oncol 26 (2008) [Abstract #LBA 5026]
16. Moch H., Sauter G., Buchholz N., et al. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol 28 (1997) 1255-1259
17. Prewett M., Rothman M., Waksal H., et al. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 4 (1998) 2957-2966
18. Ravaud A., Hawkins R., Gardner J.P., et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 26 (2008) 2285-2291
19. Rixe O., Bukowski R.M., Michaelson M.D., et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8 (2007) 975-984
20. Hutson T.E., Davis D.W., Machiels J.P., et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma: Interim results of a phase II randomized discontinuation trial. Proc Am Soc Clin Oncol 25 (2007) [Abstract 5031]
21. Hainsworth J.D., Sosman J.A., Spigel D.R., et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23 (2005) 7889-7896
22. Bukowski R.M., Kabbinavar F.F., and Figlin R.A. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol (2007)
23. Ryan C.W., Goldman B.H., Lara Jr. P.N., et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 25 (2007) 3296-3301
24. Gollob J.A., Rathmell W.K., Richmond T.M., et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25 (2007) 3288-3295
25. Tannir N.M., Zurita A.J., Heymach J.V., et al. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alpha: clinical results and biomarker analysis. Proc Am Soc Clin Oncol 26 (2008) [Abstract #5093]
26. Kondagunta G.V., Hudes G., Figlin R., et al. Sunitinib malate plus interferon in first line metastatic renal cell cancer: results of a dose-finding study. Proc Am Soc Clin Oncol 25 (2007) [Abstract 5101]
27. Feldman D.R., Ginsberg M.S., Baum M., et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 26 (2008) [Abstract #5100]
28. Cooney M.M., Garcia J.A., and Elson P. Sunitinib and bevacizumab in advanced solid tumors: a phase I trial. Proc Am Soc Clin Oncol 26 (2008) [Abstract #3530]
29. Sosman J., Flaherty K., and Atkins M.B. A phase I/II trial of sorafenib with bevacizumab in metastatic renal cell cancer patients. Proc Am Soc Clin Oncol 24 (2006) [Abstract 3031]
30. Whorf R.C., Hainsworth J., Spigel D.R., et al. Phase II study of bevacizumab and everolimus in the treatment of advanced renal cell carcinoma. Proc Am Soc Clin Oncol 26 (2008) [Abstract #5010]
31. Ravaud A., Gardner J., Hawkins R., et al. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma. Proc Am Soc Clin Oncol 24 (2006) [Abstract 4502]
32. Yang J.C. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 10 (2004) 6367S-6370S
33. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296